LITS
Lite Strategy, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
0.98
▲ 0.04 (3.88%)
MARKET · —
Price
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.96
Prev close
0.94
Day high
1.05
Day low
0.99
Volume
338.39K
Market cap
$33.67M
P/E (TTM)
—
52W range
0.69 – 5.50
Trailing performance
Returnvs SPY
1W
+11.24%
+12.6%
1M
0.00%
-3.7%
3M
-10.00%
-13.1%
6M
-10.81%
-21.9%
YTD
-25.00%
-37.3%
1Y
-78.43%
-98.4%
3Y
-85.59%
-159.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on LITS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
395.71K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 24, 26 | FLYNN JAMES P Director |
BUY | 25.00K | $21.39K | Direct |
| Dec 19, 25 | FLYNN JAMES P Director |
BUY | 70.00K | $97.70K | Direct |
| Dec 18, 25 | SCHORNSTEIN ALEXANDER Beneficial Owner of more than 10% of a Class of Security |
SELL | 690.61K | $946.14K | Direct |
| Nov 19, 25 | FLYNN JAMES P Director |
BUY | 12.10K | $22.78K | Direct |
| Sep 30, 25 | FLYNN JAMES P Director |
STOCK | 10.00K | $25.43K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
FLYNN JAMES P |
Director | 125.00K | Purchase |
SCHORNSTEIN ALEXANDER |
Beneficial Owner of more than 10% of a Class of Security | 3.67M | Sale |
Fundamentals
Market cap$33.67M
Enterprise value$26.13M
Revenue (TTM)—
Gross profit$-1.97M
EBITDA$-17.13M
Net income$-60.82M
EPS (TTM)$-2.08
Free cash flow$-13.42M
Total cash$7.54M
Total debt$0
Book value / share$1.62
Shares outstanding34.03M
Float31.82M
Short % of float0.38%
Dividend yield—
Beta (5Y)0.04
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio2.22
Price / sales—
Price / book0.61
EV / revenue—
EV / EBITDA-1.53
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-159.26%
Return on assets-27.69%
Debt / equity—
Current ratio11.53
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $65.30M | $48.82M | $40.70M | -100.0% |
| Operating revenue | $0 | $65.30M | $48.82M | $40.70M | -100.0% |
| Cost of revenue | — | — | — | $0 | — |
| Gross profit | — | — | — | $40.70M | — |
| Research & development | $3.92M | $16.56M | $52.45M | $85.64M | -76.3% |
| Selling, general & admin | $13.53M | $23.30M | $33.13M | $30.54M | -41.9% |
| Total operating expense | $17.45M | $39.86M | $85.58M | $116.18M | -56.2% |
| Operating income | -$17.45M | $25.44M | -$36.76M | -$75.48M | -168.6% |
| Net interest income | $1.03M | $3.28M | $3.35M | $284.00K | -68.7% |
| Pre-tax income | -$15.95M | $17.78M | -$31.84M | -$54.45M | -189.7% |
| Tax provision | — | — | — | $0 | — |
| Net income | -$15.95M | $17.78M | -$31.84M | -$54.45M | -189.7% |
| Net income to common | -$15.95M | $17.78M | -$31.84M | -$54.45M | -189.7% |
| Basic EPS | -2.39 | 2.67 | -4.78 | -8.75 | -189.5% |
| Diluted EPS | -2.39 | 2.67 | -4.78 | -9.99 | -189.5% |
| EBIT | -$17.45M | $25.44M | -$36.76M | -$75.48M | -168.6% |
| EBITDA | -$17.09M | $25.82M | -$36.38M | -$75.16M | -166.2% |
| Basic shares | 6.66M | 6.66M | 6.66M | 6.22M | 0.0% |
| Diluted shares | 6.66M | 6.66M | 6.66M | 6.26M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $18.01M | $3.71M | $16.91M | $15.74M | +386.1% |
| Cash & short-term investments | $18.01M | $38.34M | $100.69M | $153.25M | -53.0% |
| Accounts receivable | — | — | $0 | $0 | — |
| Total current assets | $18.29M | $40.77M | $107.53M | $167.13M | -55.1% |
| Property, plant & equipment | $0 | $606.00K | $13.28M | $10.71M | -100.0% |
| Total assets | $18.29M | $41.38M | $120.81M | $177.84M | -55.8% |
| Total current liabilities | $1.35M | $8.36M | $20.34M | $24.44M | -83.8% |
| Total debt | — | $0 | $12.73M | $9.64M | — |
| Total liabilities | $1.35M | $8.36M | $96.19M | $125.43M | -83.8% |
| Retained earnings | -$404.16M | -$388.22M | -$406.00M | -$374.16M | -4.1% |
| Shareholder equity | $16.93M | $33.02M | $24.62M | $52.41M | -48.7% |
| Working capital | $16.93M | $32.41M | $87.19M | $142.68M | -47.8% |
| Net tangible assets | $16.93M | $33.02M | $24.62M | $52.41M | -48.7% |
| Shares issued | 6.66M | 6.66M | 6.66M | 6.66M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$15.95M | $17.78M | -$31.84M | -$54.45M | -189.7% |
| Depreciation & amortisation | $368.00K | $383.00K | $386.00K | $326.00K | -3.9% |
| Stock-based compensation | -$144.00K | $2.28M | $3.59M | $8.35M | -106.3% |
| Change in working capital | -$4.85M | -$84.28M | -$24.95M | $16.88M | +94.2% |
| Operating cash flow | -$20.84M | -$50.47M | -$52.48M | -$48.75M | +58.7% |
| Capital expenditure | — | -$7.00K | -$35.00K | -$479.00K | — |
| Investing cash flow | $35.15M | $49.14M | $53.69M | $6.89M | -28.5% |
| Dividends paid | $0 | -$11.66M | $0 | — | +100.0% |
| Financing cash flow | $0 | -$11.87M | -$40.00K | $49.05M | +100.0% |
| Free cash flow | -$20.84M | -$50.48M | -$52.52M | -$49.23M | +58.7% |
| End cash position | $18.01M | $3.71M | $16.91M | $15.74M | +386.1% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $30.00K | $46.00K | $10.00K | $83.00K | $369.00K | — | -34.8% |
| Selling, general & admin | $2.73M | $3.31M | $3.10M | $2.79M | $2.40M | — | -17.2% |
| Total operating expense | $2.77M | $3.35M | $3.11M | $2.88M | $2.77M | — | -17.5% |
| Operating income | -$2.77M | -$3.35M | -$3.11M | -$2.88M | -$2.77M | — | +17.5% |
| Net interest income | $54.00K | $60.00K | $100.00K | $190.00K | $202.00K | — | -10.0% |
| Pre-tax income | -$23.69M | -$30.80M | -$3.64M | -$2.69M | -$2.57M | — | +23.1% |
| Net income | -$23.69M | -$30.80M | -$3.64M | -$2.69M | -$2.57M | — | +23.1% |
| Net income to common | -$23.69M | -$30.80M | -$3.64M | -$2.69M | -$2.57M | — | +23.1% |
| Basic EPS | -0.66 | -0.82 | -0.12 | — | -0.39 | -0.40 | +19.5% |
| Diluted EPS | -0.66 | -0.82 | -0.12 | — | -0.39 | -0.40 | +19.5% |
| EBIT | -$2.77M | -$3.35M | -$3.11M | -$2.88M | -$2.77M | — | +17.5% |
| EBITDA | -$2.77M | -$3.35M | -$3.11M | -$2.88M | -$2.77M | — | +17.5% |
| Basic shares | 35.71M | 37.37M | 29.48M | — | 6.66M | 6.66M | -4.4% |
| Diluted shares | 35.71M | 37.37M | 29.48M | — | 6.66M | 6.66M | -4.4% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7.54M | $8.76M | $10.11M | $18.01M | $20.47M | — | -13.9% |
| Cash & short-term investments | $9.63M | $8.76M | $10.11M | $18.01M | $20.47M | — | +9.9% |
| Total current assets | $10.97M | $10.91M | $13.24M | $18.29M | $20.78M | — | +0.6% |
| Property, plant & equipment | — | — | — | $0 | $0 | $0 | — |
| Total assets | $57.79M | $82.94M | $113.34M | $18.29M | $20.78M | — | -30.3% |
| Total current liabilities | $952.00K | $1.09M | $1.07M | $1.35M | $1.24M | — | -12.4% |
| Total liabilities | $952.00K | $1.09M | $1.07M | $1.35M | $1.24M | — | -12.4% |
| Retained earnings | -$462.30M | -$438.60M | -$407.80M | -$404.16M | -$401.48M | — | -5.4% |
| Shareholder equity | $56.84M | $81.85M | $112.27M | $16.93M | $19.54M | — | -30.6% |
| Working capital | $10.02M | $9.82M | $12.17M | $16.93M | $19.54M | — | +2.0% |
| Net tangible assets | $56.84M | $81.85M | $112.27M | $16.93M | $19.54M | — | -30.6% |
| Shares issued | 36.78M | 36.78M | 35.66M | 6.66M | 6.66M | — | 0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$23.69M | -$30.80M | -$3.64M | -$2.69M | -$2.57M | +23.1% |
| Depreciation & amortisation | $0 | $0 | $0 | $0 | $0 | — |
| Stock-based compensation | $270.00K | $234.00K | $284.00K | $78.00K | $16.00K | +15.4% |
| Change in working capital | $245.00K | $296.00K | -$2.12M | $149.00K | -$710.00K | -17.2% |
| Operating cash flow | -$1.52M | -$1.93M | -$4.51M | -$2.46M | -$3.27M | +21.2% |
| Investing cash flow | $2.10M | $569.00K | -$100.00M | $0 | $0 | +268.7% |
| Share buybacks | -$1.79M | — | — | — | $0 | — |
| Dividends paid | — | — | — | $0 | $0 | — |
| Financing cash flow | -$1.79M | $5.00K | $96.61M | $0 | $0 | -35,940.0% |
| Free cash flow | -$1.52M | -$1.93M | -$4.51M | -$2.46M | -$3.27M | +21.2% |
| End cash position | $7.54M | $8.76M | $10.11M | $18.01M | $20.47M | -13.9% |
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
0.01
Positioning, not flow
Max pain
2.50
+152.6% from spot
ATM implied vol
262.5%
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
304
Contracts, this expiry
Put volume
1
Contracts, this expiry
Heaviest call OI
2.50
1.56K contracts
Heaviest put OI
2.50
13 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2024 | -1.40 | -1.13 | +19.6% |
| Mar 2024 | -1.26 | -1.37 | -8.7% |
| Dec 2023 | -1.27 | -1.66 | -30.7% |
| Sep 2023 | -1.80 | 8.46 | +571.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders1.16%
Held by institutions17.31%
Institutions holding39
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.91
+7.57% from price
SMA 20
0.93
+6.00% from price
SMA 50
0.93
+6.18% from price
SMA 100
1.01
-3.15% from price
SMA 200
1.21
-18.50% from price
EMA 12
0.93
+5.40% from price
EMA 26
0.94
+4.60% from price
EMA 50
0.95
+2.68% from price
RSI (14)
57.9
Neutral
MACD (12,26,9)
-0.01
Hist 0.01
ATR (14)
0.06
6.35% of price
Realised vol 30D
51.0%
Annualised
Bollinger upper
1.01
20, 2σ
Bollinger lower
0.86
20, 2σ
50 / 200 cross
Death
0.93 vs 1.21
Trend bias
Below 200
-18.50%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.05
More volatile than market
Correlation to SPY
0.32
Loosely linked
Realised vol 30D
51.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-86.0%
Peak to trough
Max drawdown 5Y
-98.9%
Peak to trough
ATR 14
0.06
6.35% of price
Beta (reported)
0.04
5Y monthly, from filing
Short interest
Shares short
113.13K
Prior 140.84K
Change vs prior
-19.7%
Shorts covering
% of float
0.38%
Normal
% of shares out
0.33%
Against total outstanding
Days to cover
0.7
Liquid
Float
31.82M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend dateNov 16, 2023
Next pay dateDec 6, 2023
Last split1:20
Split dateApr 17, 2023
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-07-30
Corporate Changes & Voting Matters
8-K · 2026-07-24
Periodic Financial Reports
10-Q · 2026-05-13
Periodic Financial Reports
10-Q · 2026-02-17
Corporate Changes & Voting Matters
8-K · 2026-02-12
Proxy Statements
DEFA14A · 2026-01-27
Proxy Statements
DEFA14A · 2025-12-30
Corporate Changes & Voting Matters
8-K · 2025-12-05
Headlines
Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential
Stocktwits · 10d ago
Can LitVM Bring Smart Contracts to Litecoin Without Changing Its Identity?
CCN · 61d ago
Exclusive: Lite Strategy leads $1m investment in Litecoin Layer 2 platform LitVM
Investing.com · 66d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.